- Home
- AARD vs LRMR Comparison
AARD vs LRMR Comparison
Compare AARD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- LRMR
- Stock Information
- Founded
- AARD 2017
- LRMR N/A
- Country
- AARD United States
- LRMR United States
- Employees
- AARD N/A
- LRMR N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- AARD Health Care
- LRMR Health Care
- Exchange
- AARD Nasdaq
- LRMR Nasdaq
- Market Cap
- AARD 154.9M
- LRMR 183.8M
- IPO Year
- AARD 2025
- LRMR N/A
- Fundamental
- Price
- AARD $6.93
- LRMR $2.03
- Analyst Decision
- AARD Strong Buy
- LRMR Strong Buy
- Analyst Count
- AARD 4
- LRMR 9
- Target Price
- AARD $31.50
- LRMR $19.00
- AVG Volume (30 Days)
- AARD 129.3K
- LRMR 1.0M
- Earning Date
- AARD 01-01-0001
- LRMR 05-08-2025
- Dividend Yield
- AARD N/A
- LRMR N/A
- EPS Growth
- AARD N/A
- LRMR N/A
- EPS
- AARD N/A
- LRMR N/A
- Revenue
- AARD N/A
- LRMR N/A
- Revenue This Year
- AARD N/A
- LRMR N/A
- Revenue Next Year
- AARD N/A
- LRMR N/A
- P/E Ratio
- AARD N/A
- LRMR N/A
- Revenue Growth
- AARD N/A
- LRMR N/A
- 52 Week Low
- AARD $4.88
- LRMR $1.61
- 52 Week High
- AARD $19.58
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- LRMR 44.33
- Support Level
- AARD N/A
- LRMR $1.76
- Resistance Level
- AARD N/A
- LRMR $1.91
- Average True Range (ATR)
- AARD 0.00
- LRMR 0.17
- MACD
- AARD 0.00
- LRMR 0.05
- Stochastic Oscillator
- AARD 0.00
- LRMR 70.34
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.